Deorphanization of Novel Peptides and Their Receptors by Ozawa, Akihiko et al.
Review Article
Theme: Fishing for the Hidden Proteome in Health and Disease: Focus on Drug Abuse
Guest Editors: Rao S. Rapaka, LloydD. Fricker, and JonathanV. Sweedler
Deorphanization of Novel Peptides and Their Receptors
Akihiko Ozawa,1 Iris Lindberg,1,3 Bryan Roth,2,3 and Wesley K. Kroeze2
Received 24 February 2010; accepted 14 April 2010; published online 6 May 2010
Abstract. Peptide hormones and neuropeptides play important roles in endocrine and neural signaling,
often using G protein-coupled receptor (GPCR)-mediated signaling pathways. However, the rate of
novel peptide discovery has slowed dramatically in recent years. Genomic sequencing efforts have
yielded a large number of cDNA sequences that potentially encode novel candidate peptide precursors,
as well as hundreds of orphan GPCRs with no known cognate ligands. The complexity of peptide
signaling is further highlighted by the requirement for specific posttranslational processing steps, and
these must be accomplished in vitro prior to testing newly discovered peptide precursor candidates in
receptor assays. In this review, we present historic as well as current approaches to peptide discovery and
GPCR deorphanization. We conclude that parallel and combinatorial discovery methods are likely to
represent the most fruitful avenues for both peptide discovery as well as for matching the remaining
GPCRs with their peptide ligands.
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INTRODUCTION
Peptide hormones and neuropeptides play critical roles
in diverse biological phenomena, often via G protein-coupled
receptor (GPCR)-mediated signaling pathways. The success-
ful sequencing of entire genomes of many different organisms
has yielded a large number of cDNA sequences that
potentially encode novel candidate peptide precursors, as
well as hundreds of orphan GPCRs with no known cognate
ligands. Because GPCRs already represent the largest class of
target molecules for pharmaceutics, GPCR deorphanization
of novel bioactive peptides has the potential to both open
entirely new fields of research and to provide novel ther-
apeutics. However, the genomic identification of novel
bioactive peptides has been hampered by certain disadvanta-
geous properties of peptides, such as their small size and the
lack of definitive posttranslational processing information,
particularly cleavage site usage.
In the first half of this review, we present a short
discussion of the cellular mechanisms by which bioactive
peptides are synthesized. We follow with a discussion of
past methods of peptide discovery: classical and reverse-
pharmacology methods; mass spectrometric-based methods;
and bioinformatics. We then describe our recent approach to
peptide discovery using prohormone convertases as screening




Peptide hormones are initially synthesized as relatively
large precursor proteins which gradually mature into specific
bioactive forms via the sequential action of posttranslational
processing enzymes. The proprotein convertases (PCs) are
the initial processing enzymes responsible for precursor
maturation; these enzymes cleave C-terminally to single or
double basic sites (1). Furin and PACE4 are PCs which are
distributed ubiquitously and contribute to cleavage of a wide
variety of secreted proteins, for example growth factor
precursors and blood proteins, within the constitutive secre-
tory pathway (2,3). In contrast, the prohormone convertases
PC1/3 and PC2 (4,5), expressed predominantly in neuro-
endocrine tissues, represent the processing enzymes required
to produce neuropeptides and peptide hormones within the
regulated secretory pathway. The products of convertase
processing enzymes are then C-terminally trimmed, usually
by carboxypeptidase E (6,7). Other precursor-specific post-
translational modifications such as C-terminal amidation,
N- or O-acylation, tyrosine sulfation, N-glycosylation, phos-
phorylation, and even bromination can also take place; often,
these modifications are required for bioactivity (reviewed in
8–14). Amidation is the most common modification (15,16);
the other posttranslational modifications mentioned occur
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much less frequently on perhaps 10% of known neuro-
peptides and peptide hormones.
CLASSICAL AND REVERSE PHARMACOLOGICAL
APPROACHES TO NOVEL PEPTIDE DISCOVERY
The discovery of enkephalins exemplifies the now-
classical peptide discovery method, bioactivity assays coupled
with peptide purification from specific tissues (17). A more
recent approach, termed “reverse-pharmacology”, follows
peptide activity against orphan GPCRs that are cloned into
eukaryotic expression systems and coupled to various
reporter assays (18–24). With this approach, several new
peptide hormones involved in important physiological phe-
nomena were discovered within the last decade; orexin/
hypocretin, involved in sleep regulation and food intake;
ghrelin, which mediates appetitive mechanisms; and kisspep-
tin, involved in reproduction (25–27). The major advantage of
this method is the ability to couple peptide and receptor in an
unbiased manner. However, it can be difficult to identify
efficient reporter systems for an unknown receptor, since
nothing is known a priori about second messenger coupling.
There are certain methods that do not require such prior
knowledge (see below), and these are gaining increasing use
in deorphanization studies.
MASS SPECTROMETRY APPROACHES
Mass spectrometry (MS), a technique which can be both
robust and rapid, has increasingly been used in recent years
for peptide discovery. Fricker and colleagues reported the
presence of a novel brain peptide precursor known as
proSAAS (28) using mass spectroscopic analysis. This group
has also published a comprehensive analysis of brain peptides
in animals that do not express the precursor processing
enzymes CPE and PC2 (29–35). Endocrine cell lines have
also been used to identify novel peptides under specific
stimulation conditions; for example, katacalcin, a novel
peptide derived from the calcitonin precursor, has recently
been identified by MS (36).
In a more functional approach, Hatcher and colleagues
have used MS-based methods to determine the sequences of
peptides involved in circadian rhythms (37). This study used
MS to compare peptide products in the mouse brain under
light and dark circadian phases. Several novel peptides were
present (but not identifiable) as well as known small peptides
derived from proSAAS (28). Brockmann et al. have reported
an interesting MS methodology that connects the production
of neuropeptides—both novel and unknown—with behavior
in honeybees (38). These studies confirm that MS-based
methods have the potential to reveal information about
temporal and spatial expression of peptides, making this a
powerful method for the study of peptide function. Limi-
tations of the method include the need for high-end
spectrometers and the need to handle enormous amount of
information generated during MS runs, often requiring high
capacity data handling facilities coupled with special infor-
matics programs. It can also be extremely difficult to detect
scarce peptides in the presence of large quantities of other
proteins. Several different secretory granule proteomics
projects have attempted to identify the major secreted species
present within granules obtained from different tissues;
however, no peptides derived from novel precursors have
been identified to date, most likely due to these abundance
issues as well as to their focus on proteins rather than
peptides (39–41).
BIOINFORMATICS APPROACHES
With the successful revelation of the genomes of many
species, bioinformatics has become an increasingly powerful
tool to identify target peptide precursor molecules from
enormous amounts of genomic information. Three different
groups have used hidden Markov models to establish
predictive algorithms for novel peptide precursors. Mirabeau
and colleagues employed an algorithm to search for signal
peptide-bearing proteins using evolutionary conservation of
peptide sequences among species coupled with the presence
of known sequences of prohormone convertase cleavage sites
(42). This group, who concluded that there were likely to be
few further undiscovered peptides, identified precursors to
two novel peptides, termed “spexin”, expressed in esophagus
and stomach, and “augurin”, expressed in endocrine tissues
and choroid plexus (42; note that augurin had actually been
previously discovered and given the name of “ecrg4”; 43). A
second peptide discovery group used a somewhat similar
bioinformatics analysis focused on peptide conservation
across species to identify one of the same novel peptides
(spexin; 44). Lastly, Gustincich analyzed the mouse tran-
scriptome for nervous system-expressed proteins, searching
for small open reading frames containing cleavage sites (45).
Unfortunately, it is clear that novel peptide precursor
algorithms have not yet reached a satisfactory level of
predictive ability. While Gustincich identified 90 hypothetical
novel proteins, and Mirabeau over 200 potential precursor
proteins, both lists contain many intron-containing proteins,
cytokines, defensins, interleukins, and growth factors—all of
which are unlikely to represent actual protein precursors
processed within the secretory pathway. Indeed, from Mir-
abeau’s list of 300 genes of candidate peptide precursors, 200
genes are either cytokines or defensins, neither considered
likely substrates for prohormone convertases. This low
accuracy of prediction results in part from insufficiently
detailed knowledge as to specific site requirements for PC
cleavage (46). In this regard, it is useful to mention two online
cleavage prediction programs. Southey et al. have developed
the NeuroPred online program, available at the University of
Illinois site (47). While we have found this to be a very useful
program to predict prohormone cleavage sites, experimental
data indicate that this prediction algorithm is insufficiently
restrictive (48). By contrast, another online cleavage predic-
tion program, ProP 3.0, tends to underestimate the predicted
hormones (48,49) Some of this lack of predictive precision
derives from the fact that these programs attempt to predict
cleavages of both furin and PC cleavage sites, but due to the
overlapping cleavage specificities of these enzymes, it is
impossible solely from sequence data to establish which
sequences are best cleaved by the constitutive processing
enzyme furin, and which sequences are cleaved by the two
prohormone convertases PC1/3 and PC2.
In summary, at the present time, it appears to be
impossible to accurately predict all peptide hormones and
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neuropeptide precursors using only information derived from
algorithms. However, the accuracy of prediction efforts in
identifying PC-cleaved peptide hormones and neuropeptides
may improve after algorithms are better trained using a
sufficient number of experimentally-derived datasets.
COMBINATORIAL APPROACH: BIOINFORMATICS
COUPLED WITH CONVERTASE SENSITIVITY
Together with coworkers at FivePrime Therapeutics, we
have taken a combinatorial approach to the identification of
novel peptide hormones. We begin with bioinformatics to
identify novel peptide hormone candidates from the genome
which possess certain sets of traditional peptide hormone
properties. First, among these is the presence of pairs of basic
residues conserved at least between rats and mice, but other
criteria, such as typical exon number, overall size, and
secondary structure characteristics surrounding cleavage sites
are also used. We remove proteins from consideration that are
ubiquitously expressed, since peptide hormones and neuro-
peptide precursors are known to exhibit restricted patterns of
expression.We then perform prohormone convertase cleavage
screening reactions on the remaining candidate peptide
precursors, using our recombinant prohormone convertases
(50,51), either in eukaryotic expression arrays or on bacte-
rially-expressed proteins (unpublished results). Due to the
highly restricted specificity of prohormone convertases, this
step reduces the number of false-positive precursor proteins.
As described above, prohormone convertases all cleave at
motifs involving basic residues, mostly pairs of basic residues.
Each convertase differs in its preferences regarding the
residues surrounding these cleavage sites, though, as discussed
below, some overlap between convertases exists (2,52).
Their exquisite specificity for only a subset of basic
residue cleavage sites, which has led us to term the proprotein
convertases “restriction proteases” (48), may be due to their
recognition of primary and secondary structural elements that
extend beyond the actual cleavage site (46,53–55). Using
convertases to validate putative precursors in a secondary
screen reduces the problem of overly generous bioinformatics
predictions, in that proteins which contain double basic
residues—even highly conserved double basics—but do not
represent actual substrates are simply not recognized by these
proprotein convertases. In support of this idea, we have observed
many examples of proteins containing bioinformatically-
predicted pairs of basics that do not undergo convertase
cleavage in vitro. An additional benefit of this method is that we
can use MALDI-TOF mass spectroscopy to obtain direct mass
information on most of the actual peptide products of propro-
tein convertase cleavage (successful detection depends on
chemical character and length). Disadvantages of this method
arise from the overlapping specificities of the proprotein
convertases mentioned above. For example, PC2 can cleave at
certain furin sites in various precursors; however, if PC2 is not
naturally co-expressed together with the candidate precursor, it
will have no opportunity to perform this cleavage physiologically,
even though it may do so efficiently in vitro. Therefore, it is
possible to identify prohormone convertase cleavage sites
that in fact may not occur naturally. A partial solution to this
problem is to examine enzyme and precursor co-expression
patterns for each precursor, since certain tissues (for example,
liver) totally lack PC1 and PC2. However, actual coexistence of
enzyme and substrate within the same cellular compartment
must eventually be confirmed experimentally.
Once likely peptides are identified, function must be
determined. We have used recombinant processing enzyme
arrays (convertase [furin, PC1/3 or PC2], CPE, peptidyl
amidating enzyme, and glutaminyl cyclase to generate 1-
100 uM concentrations of natural peptide ligands from
bacterially and mammalian-cell expressed precursors (48
and unpublished results; PAM and glutaminyl cyclase are
added only when the primary sequence indicates that these
modifications might take place). We have previously
published on the efficacy of such an in vitro-generated
POMC-derived peptide on receptor assays (48) and have
now extended these results to proenkephalin and prodynorphin-
derived peptides (unpublished results). Our workflow for
generating known and novel peptide products is described in
Fig. 1.
In vitro processed peptides can be studied using a range
of bioassays, including testing with orphan GPCR assays as
discussed later in this review. We expect that missing process-
ing enzymes, such as sulfotransferases (required for CCK
sulfation) and acylating enzymes (required for α-MSH and
ghrelin synthesis), can be added in the future as they become
available in recombinant form. While these modifications are
rare, when present they appear to add greatly to bioactivity,
and will be required to fully recapitulate natural peptide
processing in vitro to produce functionally active ligands.
NOVEL PEPTIDE DISCOVERY: THE FUTURE
Historically-used peptide identification approaches have
resulted in the discovery of a number of novel peptide
precursors within the last two decades, namely the precursors
to adrenomedullin, nociceptin/orphaninFQ, orexin/hypocre-
tin, CART, AGRP, nesfatin, kisspeptin, pQRF/26RFamide,
and neuropeptide S (18,20–22). However, the rate of identi-
fication of novel mammalian peptide precursors has slowed
dramatically in recent years, with no new precursors identi-
fied in the last 2 years; this suggests that the approaches
discussed above might have reached their intrinsic limits. For
example, a low tissue abundance of certain peptides may
preclude further reverse pharmacology approaches, and the
low accuracy of prediction algorithms makes novel peptide
identification solely by bioinformatics problematic. Combinato-
rial bioinformatics approaches that include definitive peptide
properties—such as the ability to be made by convertases—and
either functional and/or anatomical information are likely to
represent the most fruitful approaches in the future. Mass
spectroscopic identification can address certain issues of sensi-
tivity, but still suffers from abundance issues when other proteins
overwhelm scarce signals. Important novel peptides yet to be
discovered include the many endogenous ligands of the orphan
peptide GPCRs, as discussed below, as well as many other
secreted signaling proteins likely to be involved in development,
growth and control of metabolic function.
DEORPHANIZATION OF PEPTIDE GPCRS
The human genome contains genes for roughly 400 non-
olfactory GPCRs (56,57); of these, approximately half are
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likely to be peptide GPCRs (we estimate 230). Of the GPCRs
likely to be peptide receptors (based on homology with
known peptide GPCRs), roughly half are orphans and our
current estimate is 108. Thus, there remains a great deal to be
accomplished in determining the ligands for these receptors
as well as their potential role(s) in both normal physiology
and disease. The peptide receptors, unlike some other
subfamilies of GPCRs (e.g., the biogenic amine receptors),
do not form a homogeneous group based on their sequences
(see for example (58)), but are found among several major
subgroups of GPCRs. The biology of these receptors is likely
to be similarly diverse.
In the early history of cloning (typically by homology
using degenerate oligonucleotides or low-stringency screen-
ing), almost every receptor discovered was an orphan
receptor (e.g., G-21 which was subsequently demonstrated
to be the 5-HT1A receptor (59)). The subsequent impact of
the deorphanization of these receptors and their ligands is
undeniable. While it could be argued that the law of
diminishing returns may apply, it seems probable that
continued deorphanization of GPCRs is likely to impact at
least three fronts: (1) knowledge of the physiological role of
these receptors; (2) discovery of their potential value as drug
targets; and (3) elucidation of their potential to mediate off-
target effects of both current and future therapeutics. Of
these, the latter is likely to have the most immediate impact
on human welfare and indeed new means to predict and test
off-target effects of widely used GPCR ligands are already
having considerable influence (60).
The primary challenge in deorphanization of GPCRs is,
of course, that so little is known about them. Although their
tissue distribution is well-described in various resources (e.g.,
(61), the Symatlas website [http://biogps.gnf.org/], the Allen
Brain Atlas website [http://www.brain-map.org/], and others),
and thus some preliminary inferences can be made on their
possible biological roles, experimental design is complicated
by lack of knowledge of their signaling pathways (including
their G-protein partners), and the lack of positive controls for
experimentation. However, the high degree of conservation
of the sequences of these receptors among various species
argues in favor of significant biological roles.
It is interesting that almost every new technology that is
developed to measure GPCR activation and/or signaling has
been suggested (almost immediately) to be suitable for
deorphanization (see 62–67 for examples and 68–70) for
review). However, despite the apparent suitability of many of
these assays, relatively few studies have been published that
use these assays in a systematic manner to actually deorphan-
ize receptors. Examples of assays that have been used (with
varying degrees of success), in addition to the now standard
assays of radioligand binding, calcium mobilization, GTPγs
binding, and modulation of cAMP levels in GPCR deorpha-
nization are listed in Table I below. Some of these assays are
made more practically useful by virtue of the fact that it is not
necessary to know the “true” coupling partners of the
receptors in order to carry out ligand discovery screens. It is
our experience, for example, that the “best” Gα coupling
partner of a GPCR expressed in yeast may very well not be
the same as that seen in mammalian cells, or in native tissues,
yet these GPCR-expressing yeast can be used to screen
Fig. 1. Workflow for generating known and novel peptides products




Arachidonic acid release (79)
Chimeric Gα proteins (80)
Aequorin bioluminescence (81)
Promiscuous Gα proteins (82, 83)
Forskolin-stimulated luciferase (82)
Receptor internalization (84)
Gα13 and RhoA-dependent stress fiber formation (85)
Stimulation of current in ion channel and GPCR
co-transfected Xenopus oocytes
(86)
GPCR-Gα fusion proteins (87)
Receptor chimeras (88)
Phage display (63)
Yeast fluorescent reporter assay (64)
Yeast β-galactosidase assay (66)
GPCR-promiscuous Gα fusion proteins (89)
Scintillation proximity binding assay for GTPγs (72)
β-lactamase reporter assay and inducible
receptor expression
(74)
Pigment dispersion in Xenopus melanophores (90)
Cytoskeletal rearrangement by surface
plasmon resonance
(91)
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compound libraries for GPCR ligands (Kroeze & Roth,
unpublished observations).
It can be predicted that additional newly developed
assays, for example a high-throughput ERK phosphorylation
assay (62) will also prove to be useful in GPCR deorphaniza-
tion, but to our knowledge this assay has not yet been used
for this purpose.
Many of the assays suggested for GPCR deorphanization
require specialized (and expensive) instrumentation, and are
thus unlikely to come into wide general use; however, some
assays require little (if any) such instrumentation, for example,
yeast growth assays, and yet have not been widely used for
unknown reasons, despite having been established and vali-
dated more than a decade ago (65). Since the coupling
specificity of these receptors is not known, it may be that
more “universal” assays (e.g., 71) may prove to be valuable in
deorphanization studies. Increasing miniaturization of assays
(e.g., the 1,536-well format SPA assay of Johnson et al. (72)),
or even the 3,456-well format β-lactamase reporter assay
of Mishina et al., (73) will undoubtedly lead to “economies
of scale” in large-scale deorphanization studies. The study of
Bercher (74) is of particular interest; over-expression of the
receptor (G2A, also known as GPR132), is toxic to cells, so an
inducible system of receptor expression was devised that
allowed for expansion of the cell line to be used in the absence
of receptor, followed by induction of receptor expression the
day before compound screening.
Although most of the assays listed in the table above are
best suited for agonist discovery, constitutively active receptors,
either naturally occurring or made so by mutagenesis, facilitate
discovery of inverse agonists. In an interesting study, Xiao et al.
(75) show that the constitutive activity of about 30 orphan
GPCRs differs depending on the type of Gα protein with which
they are co-expressed, and this information can easily be put to
use in the development of assays for deorphanization; however,
an additional 25 receptors showed no constitutive activity when
co-expressed with 7 different Gα proteins, so this approach will
not be useful for all receptors, or in all cell types. The arrestin
recruitment assay work published by Yin et al. (76), although
focused on orphan lipid receptors, shows the value of screening
many orphan receptors in parallel, and it is to be hoped that
similar approaches with peptide receptors in the future will be
similarly fruitful. Given the increasing understanding of the
importance of functional selectivity or biased agonism in
receptor function (77), it seems clear that it may be useful to
attempt deorphanization of GPCRs using a number of different
functional screening methods in parallel. In some cases, where
discovery of ligands for orphan receptors proves difficult, it
may be of value to use knockout mice to establish biological
functions for orphan receptors, and then to use these studies to
further guide ligand discovery efforts. Of course, it is conceiv-
able that orphan peptides such as those described here could
have non-GPCR targets as well as the GPCRs, e.g., the
peptide-gated ion channels and perhaps others yet unknown,
and in such cases different approaches to discover their targets
may need to be taken.
CONCLUSION
The combination of approaches described here for
discovery and characterization of novel peptides, as well as
for deorphanization of their receptors, holds much promise
for meaningful investigation in the near future, and it is to be
hoped that the results of studies such as these will accelerate
the development of useful therapeutics in the longer term.
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